Our Team

Artizan’s founders are among the luminaries in immunobiology, and our scientific team is comprised of experts in immunology, microbiology and drug development. We’re backed by highly respected investors and governed by a prestigious board of directors with broad industry experience.


  • Richard A. Flavell, Ph.D., D.Sc.Richard A. Flavell, Ph.D., D.Sc., is Sterling Professor of Immunobiology at Yale University School of Medicine and an Investigator of the Howard Hughes Medical Institute. He performed his postdoctoral work in Amsterdam (1970-72) with Piet Borst and in Zurich (1972-73) with Charles Weissmann. Before accepting his current position in 1988, Dr. Flavell was first Assistant Professor (equivalent) at the University of Amsterdam (1974-79); then Head of the Laboratory of Gene Structure and Expression at the National Institute for Medical Research, Mill Hill, London (1979-82); and subsequently President and Chief Scientific Officer of Biogen Research Corporation, Cambridge, Massachusetts (1982-88). He is a fellow of the Royal Society, a member of EMBO, the National Academy of Sciences and the National Academy of Medicine. Dr. Flavell served as the founding Chairman of Yale’s Department of Immunobiology for 28 years, stepping down in early 2016. He is the co-discoverer of introns in cellular genes: he showed DNA methylation correlates inversely with, and prevents, gene expression. Dr. Flavell was the first to develop reverse genetics as a postdoc, and in his own lab continued in this field throughout his career. He is a pioneer and sophisticated practitioner in the use of this approach in vivo to study function. Dr. Flavell’s laboratory studies the molecular and cellular basis of the immune response, particularly as it applies to autoimmune and autoinflammatory diseases. Recently, he elucidated mechanisms that regulate homeostasis between the microbiome and host. This work has, in part, led to the founding of Artizan Biosciences. He has published more than 1,000 peer reviewed papers and is one of the world’s most cited immunologists. Dr. Flavell received his B.Sc. (Honors) in 1967 and Ph.D. in 1970 in biochemistry from the University of Hull, England.
  • Noah W. Palm, Ph.D.Noah W. Palm, Ph.D., is an Assistant Professor of Immunobiology at Yale University School of Medicine, where his lab focuses on understanding how the trillions of microbes that live in and on us interact with and influence their mammalian hosts. His work particularly emphasizes the development of new technologies to deconvolute complex host-microbiota interactions and reveal causal and mechanistic roles for the microbiota in human health and disease. Dr. Palm is the recipient of multiple honors and awards, including a Smith Family Foundation Award for Excellence in Biomedical Research, Pew Biomedical Scholar Award and NIH Director's New Innovator Award. He received his B.A. in Biology from Macalester College and performed his doctoral work with Dr. Ruslan Medzhitov and postdoctoral studies with Dr. Richard Flavell at Yale University.
  • Dr. Marcel de Zoete, Ph.D.Dr. Marcel de Zoete, Ph.D., is Associate Professor of Microbiome Research at the Department of Medical Microbiology at the University Medical Center Utrecht in The Netherlands. During his postdoctoral studies in the lab of Professor Dr. Richard Flavell at the Department of Immunobiology at Yale University School of Medicine, Dr. De Zoete identified a subset of bacterial members of the intestinal microbiota that contribute to inflammatory bowel disease. His current research continues to focus on the molecular mechanisms through which the microbiota and its metabolites, by targeting epithelial, stromal and immune cells, influence intestinal health and disease. Dr. De Zoete has authored multiple high-impact publications, several of which appeared in Nature, Science, Cell and PNAS.


  • Ms. Chintha brings more than 10 years of industrial experience to Artizan in the fields of microbiome, virology, immunology, molecular biology and biochemistry including target validation through progressing lead candidates into clinical trials. Prior to joining Artizan, she worked as a Senior R&D Specialist in the Infectious Diseases department at Regeneron Pharmaceuticals. Ms. Chintha received her M.S. in Biological Sciences from University of Massachusetts and her B.S. in Biotechnology from Jawaharlal Nehru Technological University.
  • Prior to joining Artizan, Ms. Cooney-Walsh worked at Bristol-Myers Squibb for 13 years as a veterinary scientist where she performed lab animal research and discovered a passion for the animals that lead to many important scientific discoveries. She began her career working in a zoo and a small animal veterinary practice. She received her B.S. in Zoology from Washington State University and holds a certificate as a Laboratory Animal Technologist with the American Association for Laboratory Animal Science.
  • Dr. Silvina del Carmen earned her undergraduate degree in Biotechnology and her doctoral degree in Biochemistry from the National University of Tucuman in Argentina. Under the supervision of Drs. Jean Guy LeBlanc and Alejandra de Moreno, she studied the anti-inflammatory activity of genetically modified lactic acid bacteria and their potential use as a complementary probiotic therapy for inflammatory bowel diseases. During her Ph.D training, she naturally developed an interest in the regulation of the host innate immune response, and thus pursued further postdoctoral training in Dr. Rothlin’s lab at Yale University, where she studied the role of molecules that regulate clotting and inflammation; and in Dr. Jacques Banchereau’s lab at The Jackson Laboratory for Genomic Medicine, where she performed big data analysis for the discovery of novel splice isoforms on clinical samples of Lupus patients.
  • Dr. Hoekstra has worked in pharmaceutical R&D as a medicinal chemist and intellectual property coordinator for more than 30 years. Prior to joining Artizan, he served as Senior Vice President of Medicinal Chemistry at Viamet Pharmaceuticals Inc., where he co-invented the Phase 3 antifungal oteseconazole and the Phase 2B anticancer agent seviteronel. Prior to working with Viamet, Dr. Hoekstra held the position of Associate Director in Discovery Medicinal Chemistry at GlaxoSmithKline where he coordinated the introduction of a group of nuclear receptor modulator programs into the portfolio. In the 1990s, he directed the discovery and lead optimization of several clinical new chemical entities such as the Phase 2B antithrombotic elarofiban in Johnson & Johnson’s Department of Drug Discovery. Dr. Hoekstra has co-authored over 100 publications, holds 75 issued U.S. patents and has presented several invited lectures. He received his B.S. in Chemistry from Hope College, Holland, MI and subsequently earned his Ph.D. in Organic Chemistry from Emory University, Atlanta, GA.
  • Dr. Jain brings extensive microbiology experience to Artizan. Prior to joining Artizan, she led the microbiology department at Vanessa Research in a Hamden based company. She was instrumental in initiating an engineered phage therapy project for Cholera treatment and participated in pre-clinical research and formulation of their lead candidate, Shylicine, treatment for a rare intestinal disorder. Dr. Jain spent almost 10 years at Yale University for her postdoctoral work and focused on the molecular mechanisms for assembly of surface associated virulence factors in aerobic and anaerobic Gram-negative bacteria. In addition, she was the lead researcher in a pediatric cystic fibrosis microbiome study. Dr. Jain earned her doctorate degree from Jawaharlal Nehru University in India.
  • Mr. John brings his prior experience in the agricultural biotech industry to the Artizan team. Prior to joining the company, he worked as a microbiology research associate at Native Microbials, where he developed live microbial supplements for livestock and companion animals. As a member of the microbial discovery team at Bayer Crop Science, Mr. John helped develop microbial products intended to improve crop efficacy. He received his B.S. in Animal Biology from the University of California, Davis.
  • Ms. Ledoux has more than a decade of experience in lab management and operations in both academia and biotech, building safety programs, procurement systems and using technology to streamline laboratory operations. Prior to Artizan, she served as Laboratory Manager for Assembly Biosciences, supporting the cGMP microbiome CMC group with Phase 1 clinical supply development, manufacture and release. Ms. Ledoux is in the process of completing her Project Management Professional certification to support the therapeutic development programs as they mature. She received her B.S. in Biology from Massachusetts College of Liberal Arts.
  • Dr. Miller is the Chief Scientific Officer and is responsible for all facets of Artizan’s research and development organization and portfolio. Prior to joining Artizan in 2019, he was Chief Scientific Officer at Synlogic where he established the company’s research team and helped guide it to advance a novel, engineered, live microbial biotherapeutic platform from idea to first-in-human studies in under three years. Previously, Dr. Miller was the Vice President of Infection Biology at AstraZeneca where he was responsible for the early discovery portfolio and strategy, while also leading several external collaborations. Prior to AstraZeneca, Dr. Miller was the Chief Scientific Officer for Antibacterial Research at Pfizer, leading discovery teams that produced eight drug development candidates, provided critical research support for several successful marketed antibiotics including Zithromax and Zyvox and advanced a novel oxazolidinone (sutezolid) for tuberculosis into Phase 2 studies. A microbial geneticist by training, he began his professional career at the Warner-Lambert Company in Ann Arbor, Michigan, where he integrated cutting edge molecular-genetic approaches into a traditional antibacterial drug discovery program and established novel target discovery projects. His work there led to new insights into the mechanisms by which bacteria sense and respond to antibiotics and other environmental agents. Dr. Miller has served as a member of the Institute of Medicine’s Forum on Microbial Threats and also is a scientific advisor to the CARB-X antibacterial funding initiative as well as the Bill and Melinda Gates Foundation in the area of tuberculosis drug discovery. He received his Ph.D. in Microbiology and Immunology from the Albany Medical College and conducted post-doctoral studies in yeast genetics at the National Institutes of Health.
  • Ms. Mucha brings 25 years of executive administration experience to the Artizan team. Most recently, she worked at Alexion Pharmaceutical in the Global Business Development and Strategy Department. Additionally, Ms. Mucha spent more than 20 years in financial services at various Fortune 500 companies where she managed complex events and helped onboard and staff growing businesses. She received her B.A. in Business Administration from American InterContinental University.
  • Mr. Robinson has nearly 30 years of pharmaceutical research experience. He joined Artizan after spending a decade working to develop oncology therapeutics at two New Haven-based biotechnology companies, Kolltan and Cybrexa. He began his career studying yeast replication at the UConn Health Center and transitioned to developing small molecule and biological therapeutics targeting HIV and hepatitis C virus at Bristol-Myers Squibb and osteoporosis and diabetes at Pfizer. Mr. Robinson received his B.S. in Microbiology from the University of Connecticut.
  • Prior to Artizan’s inception, Mr. Rosen spent 12 years in venture capital, most recently leading the program-related venture capital investment function for the Bill & Melinda Gates Foundation in Seattle. Mr. Rosen spent a decade with Intersouth Partners, where he worked his way from intern to Partner on the life sciences investment team. Prior to joining Intersouth, he spent 15 years in clinical, research and financial positions in the health care and biotechnology sectors. His research experience includes programs at the Lineberger Comprehensive Cancer Center at University of North Carolina at Chapel Hill (UNC), the National Cancer Institute, Duke University Medical Center and its Comprehensive Cancer Center. Mr. Rosen also managed clinical trials at a privately held contract research organization, which led to FDA-approved products. He spent several years as an equity research analyst at Brean Murray & Co., covering biopharmaceuticals, genomics, generics, drug delivery and medical device companies. Prior to his research and Wall Street functions, Mr. Rosen spent five years in Emergency Medical Services as a mountain search & rescue and ambulance medic. He currently serves on numerous boards and advisory committees, including the UNC’s Public Health Foundation Board (Emeritus, Chairman) and Dean’s Advisory Council for the Gillings School of Global Public Health at UNC, the Carolina Research Ventures Advisory Board and the Oversight Committee for the Duke-Coulter Translational Partners Program. Mr. Rosen holds a B.A. from Duke University and an M.B.A. from UNC’s Kenan-Flagler School of Business where he was a Carolina Venture Fellow and recipient of the Frank Hawkins Kenan Award for Excellence. He received his M.S.P.H. from the UNC School of Public Health, where his thesis focused on the relationship between technology transfer in biotechnology and venture capital investment. In 2010, he was awarded the Eisenhower Fellowship for which he designed and executed a program to evaluate the prospects for health care innovation in China and Southeast Asia.
  • Dr. Schofield’s academic career focused on the molecular mechanisms that enable bacteria to propagate and thrive in the mammalian host. He completed his doctoral work in the laboratory of Christine Jacobs-Wagner, where he studied bacterial chromosome segregation by developing novel image analysis software. His post-doctoral work was done with Andrew Goodman at Yale University, where he utilized transcriptomics, metabolomics and epistasis analysis to elucidate how human gut bacteria adjust central carbon metabolism to the mammalian digestive tract.